News MSD records one hit, one miss with TL1A drug tulisokibart MSD's tulisokibart was effective in a phase 2 trial in skin disorder hidradenitis suppurativa, but has failed a study in rare lung disorder SSc-ILD.
News MSD's TL1A drug tulisokibart delivers in pivotal IBD trial MSD's tulisokibart has become the first anti-TL1A antibody to help patients with ulcerative colitis achieve clinical remission in a phase 3 trial.
News Teva, Sanofi score well with anti-TL1A drug in IBD test Phase 2b results with Sanofi and Teva's duvakitug are exciting and warrant a swift move to phase 3 in inflammatory bowel disease, say the companies.
News UK MHRA authorises orforglipron private prescription Eli Lilly has announced that orforglipron (Foundayo) is now available to be prescribed for eligible adults via private prescription.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.